L3VLUP
ProSign in

REPL · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

REPLARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • REPL
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterREPLARGX
Q3 20201 holders, $23m8 holders, $3.6bn
Q4 20202 holders, $32m7 holders, $4.1bn
Q1 20211 holders, $19m8 holders, $4.1bn
Q2 2021none listed holders, n.a.9 holders, $4.6bn
Q3 2021none listed holders, n.a.8 holders, $4.5bn
Q4 2021none listed holders, n.a.9 holders, $5.3bn
Q1 20221 holders, $15m8 holders, $5.3bn
Q2 2022none listed holders, n.a.13 holders, $6.5bn
Q3 2022none listed holders, n.a.14 holders, $5.3bn
Q4 20222 holders, $150m13 holders, $5.5bn
Q1 20231 holders, $5.5m13 holders, $5.9bn
Q2 20233 holders, $168m18 holders, $6.6bn
Q3 20233 holders, $47m21 holders, $8.7bn
Q4 20231 holders, $2.5m17 holders, $6.3bn
Q1 20241 holders, $2.4m13 holders, $6.8bn
Q2 20243 holders, $13m14 holders, $7.9bn
Q3 20244 holders, $16m13 holders, $10.7bn
Q4 20243 holders, $20m14 holders, $12.3bn
Q1 20254 holders, $40m17 holders, $11.8bn
Q2 20252 holders, $13m18 holders, $10.8bn
Q3 2025none listed holders, n.a.16 holders, $13.8bn
Q4 2025none listed holders, n.a.16 holders, $14.8bn
Q1 20261 holders, $2.4m11 holders, $12.3bn
Q2 20262 holders, $12m14 holders, $15.0bn
REPL

Replimune Group Inc

Holders
4
Reported value
$16m
Buyers
2
Sellers
1

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
13
Reported value
$10.7bn
Buyers
7
Sellers
7

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 15 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only REPL (2)

PDT Partners LLC, Schonfeld Strategic Advisors LLC

Only ARGX (11)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), Holocene Advisors LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, T. Rowe Price Associates Inc, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →